Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065294 · ClinicalTrials.gov registry record · Phase 2
Psilocybin Therapy for Depression in Bipolar II Disorder
A Phase 2 study of Bipolar II Disorder, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT05065294: Active Phase 2 study of Bipolar II Disorder, sponsored by University of California, San Francisco.
NCT05065294 is a Phase 2 study of Bipolar II Disorder that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 14 participants, below the 82-participant average among 14 other Bipolar II Disorder trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05065294, a Phase 2 study of Bipolar II Disorder, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.
Primary Outcome
-Incidence, severity, and frequency of Adverse Events (AEs) including Treatment-Emergent AEs (TEAEs) and Serious AEs (SAEs)
Conditions Studied
Interventions
- DRUG Psilocybin therapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2025-07 |
| Phase | Phase 2 |
What the registry record for NCT05065294 still lists
NCT05065294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 82-participant average among 14 other Bipolar II Disorder trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Bipolar II Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin therapy is the first listed.
NCT05065294 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05065294 about?
NCT05065294 is a clinical study titled "Psilocybin Therapy for Depression in Bipolar II Disorder". The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.
What is the current status of trial NCT05065294?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2022-01-28. Estimated completion is 2025-07.
What conditions does trial NCT05065294 study?
This clinical trial studies the following conditions: Bipolar II Disorder.
What interventions are being tested in trial NCT05065294?
The interventions under investigation include: Psilocybin therapy (DRUG).
Who is sponsoring clinical trial NCT05065294?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05065294 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar II Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05065294's enrollment target sits among peer trials
14 13th of 14 higher than 2 of 14 other Bipolar II Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar II Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
RECRUITING · Phase 2
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
RECRUITING · Phase 2
-
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
RECRUITING · Phase 2
-
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy